Bright Minds Biosciences (DRUG) Income from Continuing Operations (2023 - 2026)
Bright Minds Biosciences' (DRUG) quarterly Income from Continuing Operations came in at 35513.28 in Q4 2024, up 102.87% YoY from 17505.39 in Q1 2024, and down 78.87% on a QoQ basis from 168091.41 in Q2 2024.
Powered by 
Analysis
Bright Minds Biosciences (DRUG) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Bright Minds Biosciences (DRUG) has 2 years of Income from Continuing Operations data on file, last reported at 35513.28 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Bright Minds Biosciences | 464.96 Mn | 242.42 Mn | - | -3.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.75 Mn |
| Mar 31, 2026 | -9.59 Mn |
| Dec 31, 2025 | -6.01 Mn |
| Sep 30, 2025 | -9.80 Mn |
| Jun 30, 2025 | 4.13 Mn |
| Mar 31, 2025 | 2.35 Mn |
| Dec 31, 2024 | 32,422.24 |
| Sep 30, 2024 | -2.08 Mn |
| Jun 30, 2024 | 157,133.80 |
| Mar 31, 2024 | 1.25 Mn |
| Dec 31, 2023 | -1.24 Mn |
| Sep 30, 2023 | -5.50 Mn |
| Jun 30, 2023 | -1.09 Mn |